Onabotulinumtoxin A for chronic migraine with medication overuse

clinical results of a long-term treatment

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of Onabotulinumtoxin A as treatment for different neurological conditions is more common in the last decades; its application has been consolidated on the basis of significant clinical results. The clinical experiences with Onabotulinumtoxin A for chronic migraine are on the increase in Italy: at the moment, clinical results are encouraging and enforce the application of the toxin for chronic migraine, according to the results of the PREEMPT studies. The possibility for the patients to be treated with a second cycle of therapy after the first year of treatment is under discussion, in particular for patients who obtained significant clinical benefit from the first period of treatment. In this report, a group of patients treated with Onabotulinumtoxin A for 1 year, according to the PREEMPT protocol, has been retreated for one more year in order to confirm the clinical benefit obtained after the first year of treatment.

Original languageEnglish
Pages (from-to)141-143
Number of pages3
JournalNeurological Sciences
Volume38
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Migraine Disorders
Therapeutics
Italy
onabotulinumtoxinA
Prescription Drug Overuse

Keywords

  • Chronic migraine
  • Medication overuse
  • Onabotulinumtoxin A
  • PREMPT
  • Retreatment

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

@article{1e07c33fed2a4ee2baf13c154d7c2dfa,
title = "Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment",
abstract = "The use of Onabotulinumtoxin A as treatment for different neurological conditions is more common in the last decades; its application has been consolidated on the basis of significant clinical results. The clinical experiences with Onabotulinumtoxin A for chronic migraine are on the increase in Italy: at the moment, clinical results are encouraging and enforce the application of the toxin for chronic migraine, according to the results of the PREEMPT studies. The possibility for the patients to be treated with a second cycle of therapy after the first year of treatment is under discussion, in particular for patients who obtained significant clinical benefit from the first period of treatment. In this report, a group of patients treated with Onabotulinumtoxin A for 1 year, according to the PREEMPT protocol, has been retreated for one more year in order to confirm the clinical benefit obtained after the first year of treatment.",
keywords = "Chronic migraine, Medication overuse, Onabotulinumtoxin A, PREMPT, Retreatment",
author = "Licia Grazzi",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10072-017-2864-2",
language = "English",
volume = "38",
pages = "141--143",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Onabotulinumtoxin A for chronic migraine with medication overuse

T2 - clinical results of a long-term treatment

AU - Grazzi, Licia

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The use of Onabotulinumtoxin A as treatment for different neurological conditions is more common in the last decades; its application has been consolidated on the basis of significant clinical results. The clinical experiences with Onabotulinumtoxin A for chronic migraine are on the increase in Italy: at the moment, clinical results are encouraging and enforce the application of the toxin for chronic migraine, according to the results of the PREEMPT studies. The possibility for the patients to be treated with a second cycle of therapy after the first year of treatment is under discussion, in particular for patients who obtained significant clinical benefit from the first period of treatment. In this report, a group of patients treated with Onabotulinumtoxin A for 1 year, according to the PREEMPT protocol, has been retreated for one more year in order to confirm the clinical benefit obtained after the first year of treatment.

AB - The use of Onabotulinumtoxin A as treatment for different neurological conditions is more common in the last decades; its application has been consolidated on the basis of significant clinical results. The clinical experiences with Onabotulinumtoxin A for chronic migraine are on the increase in Italy: at the moment, clinical results are encouraging and enforce the application of the toxin for chronic migraine, according to the results of the PREEMPT studies. The possibility for the patients to be treated with a second cycle of therapy after the first year of treatment is under discussion, in particular for patients who obtained significant clinical benefit from the first period of treatment. In this report, a group of patients treated with Onabotulinumtoxin A for 1 year, according to the PREEMPT protocol, has been retreated for one more year in order to confirm the clinical benefit obtained after the first year of treatment.

KW - Chronic migraine

KW - Medication overuse

KW - Onabotulinumtoxin A

KW - PREMPT

KW - Retreatment

UR - http://www.scopus.com/inward/record.url?scp=85019595736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019595736&partnerID=8YFLogxK

U2 - 10.1007/s10072-017-2864-2

DO - 10.1007/s10072-017-2864-2

M3 - Article

VL - 38

SP - 141

EP - 143

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -